Go to deals
Healthcare

Time-Cap Labs, Inc. has been acquired by Marksans Pharma Ltd.

The founder and owner of Time-Cap Labs, Inc. has sold the company to Marksans Pharma Limited for an undisclosed consideration.

Founded in 1978 and based in Farmingdale, New York, Time-Cap Labs, Inc. manufactures and supplies generic pharmaceuticals and over-the-counter drugs. The company specializes in delayed and sustained release dosages. It offers various formulations, including analgesics, laxatives, dietary supplements, cough and cold medications, prescription drugs, antacids, and other products. The company offers its products to large and small wholesalers and distributors.

Marksans Pharma Limited, together with its subsidiaries, is engaged in the research, manufacture, and marketing of generic pharmaceutical formulations worldwide. Its product portfolio covers primary therapeutic segments of CVS, analgesics, decongestants, gastrointestinal, cardiovascular, anti-diabetics, central nervous system, oncology, anti-allergic drugs, and others. It also manufactures and distributes over-the-counter pharmaceutical products in the areas of cough and cold remedies, galenicals, vitamins, palliative and healthcare items, oils, antiseptics, and disinfectants; and offers contract research and manufacturing services to global pharmaceutical companies. Marksans Pharma Limited is headquartered in Mumbai, India.

One of Oaklins' teams in the USA served as the exclusive financial advisor to the seller in this transaction.

Service
M&A sell-side
Parties

Talk to the deal team

 Paul R. Smolevitz

Paul R. Smolevitz

Managing Director
New York, United States
Oaklins TM Capital
 James  McLaren

James McLaren

Managing Director
New York, United States
Oaklins TM Capital
 Vidur  Kapur

Vidur Kapur

Associate Director
New York, United States
Oaklins TM Capital

Related deals

SulAmérica and Rede D’Or São Luiz have announced a combination
Financial Services | Healthcare

SulAmérica and Rede D’Or São Luiz have announced a combination

SulAmérica (B3:SULA11), a leading insurance company in Brazil, has announced a combination with Rede D’Or São Luiz S.A. (B3:RDOR3), the largest Brazilian hospital network. The companies had a combined market value of approximately US$21 billion on 18 February 2022.

Learn more
Laboratoire Dazont has been acquired by SBM Company
Healthcare

Laboratoire Dazont has been acquired by SBM Company

The shareholders of Laboratoire Dazont have sold the company to SBM Company.

Learn more
Monument MicroCap Partners has sold Montgomery DME to Incline Equity Partners
Private Equity | Healthcare

Monument MicroCap Partners has sold Montgomery DME to Incline Equity Partners

Monument MicroCap Partners, LLC (MMP) has sold Montgomery DME (MDME) to Incline Equity Partners.

Learn more